Bupropion
- TRADE NAMES: Wellbutrin (GSK); Zyban (GSK)
- INDICATIONS: Depression, aid to smoking cessation
- CLASS: Antidepressant, Dopamine reuptake inhibitor
- HALF-LIFE: 14 hours
Amitriptyline, Citalopram, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Cyclosporine, Deutetrabenazine, Efavirenz, Eluxadoline, Erythromycin, Escitalopram, Isocarboxazid, Levodopa, Linezolid, Lopinavir, Lorcaserin, Methylphenidate, Mifepristone, Phenelzine, Ritonavir, Tranylcypromine, Trimipramine, Vortioxetine
PREGNANCY CATEGORY: C
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of naltrexone/bupropion in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/03/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
